xRead - Olfactory Disorders (September 2023)

First page Table of contents Previous page 109 Next page Last page

20426984, 2022, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22929, Wiley Online Library on [04/09/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

421

PATEL et al.

TABLE VII.12 (Continued)

Study design Study groups

Clinical end point UPSIT R Changes in

Topic

Study

Year LOE

Conclusions

Devanand et al 663

Although intranasal anticholinergic challenge–induced initial odor ID decline, which reflects greater cholinergic deficiency, the decline was not associated with better cognitive efficacy from a 52-week treatment with a cholinesterase inhibitor This is a failure to replicate the findings of an earlier smaller study 640 discrimination but not threshold Poorer memory associated with poorer discrimination and ID but not threshold No correlations with CSF levels of tau, P-tau, or A β 1-42 Lower odor ID performance was predictive of cognitive decline, an effect most pronounced amongApoE ε 4carriers Lower SS-ID scores and higher neuronal-derived exosomeA β 1-42 levels in AD and MCI at baseline SS-ID predicted conversion toAD SS-ID + neuronal-derived exosomeA β 1-42 levels provided stronger prediction 142 of the sample diagnosed with dementia, one of several factors correlated behavior, education, body weight, head injury, and nasal sinus disease) Prevalence of OI was 67.6% Quantitative meta-analysis indicates slight olfactory deficits in SCD compared withHCs AD and MCI showed deficits on ID and with smell loss (others included age, smoking

2020 3

Cohort

100MCI

ADAS-Cog total score and, SRT total immediate recall from baseline to 52 weeks

Doorduijn et al 664

2020 4

Case

30AD 22MCI 40HCs

SS-TDI Cognitive tests of 5domains

control

Olofsson et al 665

Sniffin’ test of OM

2020 3

Cohort

1637 patients

aged 60 to 96 years

Zhaoet al 666

2020 3

Cohort

88ADat

SS-ID (16 odors)

baseline 80HCs at baseline 87 MCI with 2

and3-year follow-up

DongY 667

SS-ID (16 odors)

2021 3

Cohort

4514 rural Chinese

patients aged > 64years

Jobinet al 668

2021 1